Sinovac Biotech Ltd.

NASDAQ: SVA · Real-Time Price · USD
6.47
0.00 (0.00%)
At close: Feb 11, 2025, 6:18 AM

Sinovac Biotech Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
448.27M 1.49B 19.37B
Cost of Revenue
181.52M 684.46M 1.07B
Gross Profit
266.75M 808.3M 18.3B
Operating Income
-546.72M -466.07M 17.55B
Interest Income
85.11M 190.82M 102.57M
Pretax Income
-153.03M 25.24M 17.56B
Net Income
-99.92M 113.87M 8.47B
Selling & General & Admin
466.32M 823.54M 591.17M
Research & Development
344.51M 442.11M 155.04M
Other Expenses
2.64M n/a n/a
Operating Expenses
813.48M 1.27B 748.45M
Interest Expense
2.26M 1.26M 2.84M
Selling & Marketing Expenses
n/a n/a n/a
Cost & Expenses
994.99M 1.95B 1.82B
Income Tax Expense
105.32M -62.89M 3.1B
Shares Outstanding (Basic)
99.61M 99.5M 99.31M
Shares Outstanding (Diluted)
99.61M 114.17M 114.01M
EPS (Basic)
-1.06 1.08 85.20
EPS (Diluted)
-1.06 1.00 74.27
EBITDA
-6.03M 183.1M 17.65B
EBIT
-150.77M 26.5M 17.57B
Depreciation & Amortization
144.75M 156.6M 100.43M